Officials break ground on park expansion in Atlanta's West End
Atlanta Mayor Andre Dickens, Atlanta Beltline, Inc. President and CEO Clyde Higgs, state officials, and other community leaders broke ground on an expansion of Enota Park on Tuesday.
Beltline officials say the expansion will take the park from a 0.3-acre playlot to an 8-acre recreational destination.
The project is scheduled for completion in Spring 2026.
The expanded park will feature three distinct areas that will include a sheltered seating area, a lawn for community gatherings and recreation, a splash pad and play area, a half-court basketball court, and bathrooms.
Security cameras, guard rails, and retaining walls will also be installed on-site.
'This original idea is now 16 years old, and we're finally able to bring this to fruition for the neighborhood,' Kevin Burke, ABI's Director of Design, said. 'Among other reasons, I'm especially glad that I've been able to stay with the project and be able to be a part of the team that has designed and will construct this park.'
[DOWNLOAD: Free WSB-TV News app for alerts as news breaks]
TRENDING STORIES:
Veteran Atlanta Country music radio personality 'Cadillac Jack' has died at age 51
Paramedic accused of assaulting patient in ambulance in Cobb County
Mother describes horrifying moments as she watched her SUV burst into flames along GA 400
[SIGN UP: WSB-TV Daily Headlines Newsletter]
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
34 minutes ago
- Yahoo
Bernstein Maintains a Market Perform Rating on Etsy (ETSY), Sets Price Target at $45
Bernstein SocGen Group maintained a Market Perform rating on Etsy, Inc. (NASDAQ:ETSY) with a price target of $45 on June 5. The analysts observed that growing investor confidence and potential short covering led Etsy shares to climb 32% since last month. A young woman shopping for a vintage fashion item online. Bernstein analysts noted that the upward momentum in Etsy, Inc. (NASDAQ:ETSY) stock is due to stronger alternative data indicating a slowdown in the annual decline of Gross Merchandise Sales in May. This data demonstrates an optimistic outlook for Etsy's growth, particularly compared to its prior lower trading multiples. The stock has gained significant ground, rising 16.15% over the last week and 16.37% so far this year. Although the main driver of this upward swing in the stock remains unclear, the analysts commented that lower traffic for Temu, an Etsy competitor, in May could be a catalyst. They also said that possible changes in products listed at Etsy could be behind this positive trajectory. The report pointed to stronger credit card spending in May and a rise in monthly app usage for Etsy, Inc. (NASDAQ:ETSY), which coincided with Temu witnessing a 43% drop in active users year-over-year. Although the analysts acknowledged that their data might not perfectly match Etsy's reported Gross Merchandise Sales, the overall signals suggest things are moving in a positive direction. Etsy, Inc. (NASDAQ:ETSY) runs global online marketplaces that bring together buyers and sellers through its main platform, Etsy, as well as Reverb for musical instruments and Depop for fashion resale. While we acknowledge the potential of ETSY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. Read Next: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 hours ago
- Yahoo
Confused by latest order? How to calculate if your Jackson County assessment is within limits
KANSAS CITY, Mo. — Jackson County assessments are showing up in homeowner's mailboxes. Some people may be surprised at the increase after a May order from the State Tax Commission. Some taxpayers may receive tax refunds in June: When payments could arrive That order capped increases in each assessment period at 15% and set 2022 as a starting point for this year's assessments after 2023 assessments were heavily contested. But determining your maximum 2025 assessment is a little bit more complicated than a single multiplication or division. Legislator Sean Smith and Preston Smith (no relation) have been helping homeowners with appeals since assessments skyrocketed in 2023. This week as they went out again they've been getting questions about what the latest State Tax Commission Order and 15% cap really means. 'People look at it and the first thing they see is, I thought it was only going to be a 15% increase and that was the perception. I've probably answered it online 100 times,' Preston Smith said. 'A lot of people are contacting me thinking they only do the 15 percent once, but you have to do it twice,' Legislator Sean Smith explained. To illustrate how it works with the latest rules using 2022 assessments as the starting point, consider a home with a $100,000 assessed value in 2022. To calculate the maximum assessed value in 2023 multiply $100,000 by 1.15 which is $115,000. But then you have to multiply by 115% again to determine the maximum value a home could be assessed at this year. In this example it would be $132,250. The two 15% increases end up yielding a maximum increase of 32.25% during the two assessment periods. 'I would really urge people to do the math themselves to check it, check and really verify,' Preston Smith said. To do that, however, you have to know your home's 2022 assessed value, which according to those who have received this year's assessments, isn't on this year's notices. You can find that historical information online at the Jackson County Parcel Viewer or Ascend Web. If your increase ends up beyond the allowances under the State order or if you simply don't agree with your value, you still can appeal. Appeals have to be filed by July 14. Download WDAF+ for Roku, Fire TV, Apple TV As for seniors, 40,000 are already enrolled in a new tax credit program freezing tax bills. The county says estimated savings are included on notices, but are subject to change. Both Sean and Preston Smith say they are pressing the Assessor's Office for complete assessment data in 2022, 2023 and 2025 to see how much home values increased, and how many of those increases equated to the maximum allowed if no new construction was done under the State Tax Commission Order without a physical inspection. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
5 hours ago
- Yahoo
H.C. Wainwright Reiterates Buy Rating on Immix Biopharma (IMMX) Following Promising Interim Results from NXC-201 Trial
On June 4, analyst Robert Burns of H.C. Wainwright reiterated a Buy rating on Immix Biopharma, Inc. (NASDAQ:IMMX) with a price target of $7.00. The analyst based the rating on the promising interim results from the NEXICART-2 Phase 1/2 clinical trial of NXC-201, presented at the 2025 American Society of Clinical Oncology Annual Meeting (ASCO 2025) in Chicago, Illinois. The trial assessed the efficacy of NXC-201 in patients with relapsed/refractory AL amyloidosis and delivered a 100% response rate, with a considerable portion attaining a complete hematologic response. The analyst reasoned that the absence of hematologic relapse or progression and the rapid mean time to response further highlight NXC-201's potential as a viable treatment. A doctor in a white coat discussing clinical trial results with a patient in an oncology practice. Burns also reasoned that NXC-201 appears to have a favorable safety profile, as no patients experienced severe cytokine release syndrome or neurotoxicity. While he highlighted the need for longer-term follow-up and the small sample size, the analyst stated that the interim results are promising when compared to existing treatments. This condition does not have FDA-approved agents, and there exists a fragmented treatment landscape post-frontline therapy, factors that suggest the notable market opportunity for NXC-201 and support the buy rating for Immix Biopharma, Inc. (NASDAQ:IMMX). Immix Biopharma, Inc. (NASDAQ:IMMX) is a biopharmaceutical company that develops therapies for inflammatory diseases and cancer. While we acknowledge the potential of IMMX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Sign in to access your portfolio
